跳转至内容
Merck
CN
  • Amelioration of Tau pathology and memory deficits by targeting 5-HT7 receptor.

Amelioration of Tau pathology and memory deficits by targeting 5-HT7 receptor.

Progress in neurobiology (2020-08-26)
Josephine Labus, Kian-Fritz Röhrs, Jana Ackmann, Hristo Varbanov, Franziska E Müller, Shaobo Jia, Kathrin Jahreis, Anna-Lena Vollbrecht, Malte Butzlaff, Yvonne Schill, Daria Guseva, Katrin Böhm, Rahul Kaushik, Monika Bijata, Philippe Marin, Séverine Chaumont-Dubel, Andre Zeug, Alexander Dityatev, Evgeni Ponimaskin
摘要

Tauopathies comprise a heterogeneous family of neurodegenerative diseases characterized by pathological accumulation of hyperphosphorylated Tau protein. Pathological changes in serotonergic signaling have been associated with tauopathy etiology, but the underlying mechanisms remain poorly understood. Here, we studied the role of the serotonin receptor 7 (5-HT7R), in a mouse model of tauopathy induced by overexpressing the human Tau[R406W] mutant associated with inherited forms of frontotemporal dementia. We showed that the constitutive 5-HT7R activity is required for Tau hyperphosphorylation and formation of highly bundled Tau structures (HBTS) through G-protein-independent, CDK5-dependent mechanism. We also showed that 5-HT7R physically interacts with CDK5. At the systemic level, 5-HT7R-mediated CDK5 activation induces HBTS leading to neuronal death, reduced long-term potentiation (LTP), and impaired memory in mice. Specific blockade of constitutive 5-HT7R activity in neurons that overexpressed Tau[R406W] prevents Tau hyperphosphorylation, aggregation, and neurotoxicity. Moreover, 5-HT7R knockdown in the prefrontal cortex fully abrogates Tau[R406W]-induced LTP deficits and memory impairments. Thus, 5-HT7R/CDK5 signaling emerged as a new, promising target for tauopathy treatments.

材料
产品编号
品牌
产品描述

Sigma-Aldrich
Fluoromount 水性封片剂, for use with fluorescent dye-stained tissues
Sigma-Aldrich
Triton X-100, BioXtra
Sigma-Aldrich
甘氨酸, BioUltra, Molecular Biology, ≥99.0% (NT)